Literature DB >> 23599173

Sex determining region Y-box 2 inhibits the proliferation of colorectal adenocarcinoma cells through the mTOR signaling pathway.

Hui Liu1, Lutao Du, Zhihua Wen, Yongmei Yang, Juan Li, Zhaogang Dong, Guixi Zheng, Lili Wang, Xin Zhang, Chuanxin Wang.   

Abstract

Sex determining region Y-box 2 (SOX2), is a high mobility group box transcription factor involved in the maintenance of pluripotency and the self-renewal of embryonic and neuronal stem cells, which also plays differential roles in the cell proliferation of several tumors. However, its role in colorectal adenocarcinoma cell proliferation and the underlying mechanisms remain unclear. The mammalian target of rapamycin (mTOR) signaling pathway has recently emerged as an important regulator of cell proliferation in many types of cancer. In this study, we examined the effect of SOX2 on the proliferation of colorectal adenocarcinoma cells and evaluated the role of the mTOR pathway in this process. Our results indicated that the overexpression of SOX2 significantly inhibited the proliferation of colorectal adenocarcinoma cells. Of note, mechanistic investigations revealed that SOX2 inhibited the activation of the mTOR pathway in HT-29 cells. We then examined the effect of SOX2 on the cell cycle, and the results revealed that SOX2 downregulated cyclin D1 expression and induced G0/G1 arrest in the HT-29 cells. Moreover, we also analyzed the correlation between SOX2 expression and patient clinicopathological characteristics in colorectal adenocarcinoma tissues, as well as the level of phospho-S6 (S235/236), phospho-Akt (S473) and cyclin D1. The results revealed a significant negative correlation between SOX2 expression and tumor size and the levels of phospho-S6 (S235/236), phospho-Akt (S473) and cyclin D1. Taken together, to our knowledge, our findings suggest for the first time that SOX2 suppresses colorectal adenocarcinoma cell proliferation through the inhibition of the mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23599173     DOI: 10.3892/ijmm.2013.1354

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  DNA methylation levels and long-term trihalomethane exposure in drinking water: an epigenome-wide association study.

Authors:  Lucas A Salas; Mariona Bustamante; Juan R Gonzalez; Esther Gracia-Lavedan; Victor Moreno; Manolis Kogevinas; Cristina M Villanueva
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

2.  SOX2 inhibits cell proliferation and metastasis, promotes apoptotic by downregulating CCND1 and PARP in gastric cancer.

Authors:  Jianfei Luo; Ruicheng Yan; Xiaobo He; Jie He
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

Review 3.  SOX2 and cancer: current research and its implications in the clinic.

Authors:  Kasia Weina; Jochen Utikal
Journal:  Clin Transl Med       Date:  2014-07-04

4.  Pharmacological activation of estrogen receptors-α and -β differentially modulates keratinocyte differentiation with functional impact on wound healing.

Authors:  Vlasta Peržeľová; František Sabol; Tomáš Vasilenko; Martin Novotný; Ivan Kováč; Martin Slezák; Ján Ďurkáč; Martin Hollý; Martina Pilátová; Pavol Szabo; Lenka Varinská; Zuzana Čriepoková; Tomáš Kučera; Herbert Kaltner; Sabine André; Hans-Joachim Gabius; Pavel Mučaji; Karel Smetana; Peter Gál
Journal:  Int J Mol Med       Date:  2015-09-21       Impact factor: 4.101

5.  Loss of MEN1 activates DNMT1 implicating DNA hypermethylation as a driver of MEN1 tumorigenesis.

Authors:  Ziqiang Yuan; Carmen Sánchez Claros; Masako Suzuki; Elaine C Maggi; Justin D Kaner; Noah Kinstlinger; Jolanta Gorecka; Thomas J Quinn; Rula Geha; Amanda Corn; Jessica Pastoriza; Qiang Jing; Asha Adem; Hao Wu; Girum Alemu; Yi-Chieh Du; Deyou Zheng; John M Greally; Steven K Libutti
Journal:  Oncotarget       Date:  2016-03-15

Review 6.  The dark side of SOX2: cancer - a comprehensive overview.

Authors:  Erin L Wuebben; Angie Rizzino
Journal:  Oncotarget       Date:  2017-07-04

Review 7.  Functional characterization of SOX2 as an anticancer target.

Authors:  Shizhen Zhang; Xiufang Xiong; Yi Sun
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

8.  Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis.

Authors:  Kun Song; Jingduo Hao; Zuyin Ge; Pushi Chen
Journal:  J Oncol       Date:  2020-02-13       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.